SCHEMBL2656112

SCHEMBL2656112

CC(NC(=O)N(Cc1ccc(C(O)Cc2nn[nH]n2)cc1)c1ccc2c(c1)CCC2)c1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.41
ACACB O00763 1/20 0.37
MEN1 O00255 2/20 0.35
CNR1 P21554 1/20 0.35
HTT P42858 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
FPR2 P25090 2/20 0.34
PARP1 P09874 1/20 0.34
FFAR2 O15552 2/20 0.33
LTB4R2 Q9NPC1 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658750 0.93 KEAP1 (0.37) KMT2AMEN1CYP1A2CYP2C19RXRA
SCHEMBL2656110 0.92 ACACB (0.37) KMT2AALDH1A1HSP90AA1GAAACACB
SCHEMBL2656191 0.88 ECE1 (0.38) KMT2AACACBMEN1CNR1CYP1A2
SCHEMBL2644303 0.85 GCGR (0.39) KMT2AMEN1CNR1FPR2LTB4R2
SCHEMBL2644086 0.85 GCGR (0.39) KMT2AMEN1CNR1FPR2LTB4R2
SCHEMBL2643503 0.85 GCGR (0.39) KMT2AMEN1CNR1FPR2LTB4R2
SCHEMBL2643975 0.85 GCGR (0.39) KMT2AMEN1CNR1FPR2LTB4R2
SCHEMBL2643499 0.85 GCGR (0.39) KMT2AMEN1CNR1FPR2LTB4R2
SCHEMBL2656108 0.84 FFAR2 (0.38) KMT2AMEN1CNR1FPR2FFAR2
SCHEMBL2643665 0.84 GCGR (0.40) FPR2FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203946-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203946-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR KMT2A 3268/4885ALDH1A1 3770/4885HSP90AA1 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.